Skoči na glavni sadržaj

Pregledni rad

Glycoconjugates and lectins in development of new medications

Olga Gornik
Mirna Flögel
Gordan Lauc


Puni tekst: hrvatski pdf 397 Kb

str. 25-31

preuzimanja: 339

citiraj

Puni tekst: engleski pdf 397 Kb

str. 25-31

preuzimanja: 103

citiraj


Sažetak

Glycans are the most abundant and most diverse biopolymers in nature. Because of their highly specific interactions with physiological receptors they participate in many crucial physiological processes. All these processes are potential targets for therapeutic intervention, and carbohydrate-based drugs are rapidly being taken up by the modern biotechnology and pharmaceutical industry. Recent developments in the field of glycobiology have overcome the problem of glycan analysis and synthesis; and now many compounds based on carbohydrates are now in various stages of clinical trials. This article presents glycoproteins in a new light, as an important biopharmaceutical target, giving an overview of their potential use as therapeutic glycoproteins and proteoglycans, inflammation blockers, cancer therapeutics and vaccines, inhibitors of pathogenic microbes, viral inhibitors and potential aids in the treatment of lysosomal diseases, neurological diseases and transplantation rejection.

Ključne riječi

Glycoproteins; Lectins; Therapeutics

Hrčak ID:

191052

URI

https://hrcak.srce.hr/191052

Datum izdavanja:

1.12.2006.

Podaci na drugim jezicima: hrvatski

Posjeta: 903 *